• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    COVID Activity Is Elevated Across 26 States In Summer Surge, Biden Remains In Isolation: 3 Vaccine Stocks To Watch

    7/18/24 3:59:25 PM ET
    $MRNA
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $MRNA alert in real time by email

    More than half of the states in the U.S. are experiencing significant Covid-19 activity in wastewater, and President Joe Biden remains in isolation after announcing Wednesday he caught the virus for the third time.

    Twenty-six states are reporting either “high” or “very high” levels of the virus at various sites, according to the latest data from the Centers for Disease Control and Prevention.

    States with the highest levels include Arkansas, California, Florida, Maryland, Nevada, Oregon and Texas.

    The Biden administration no longer considers Covid-19 a public health emergency and instead treats it as a routine respiratory virus to be prevented through an annual vaccination campaign, the Washington Post reported.

    Also Read: European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen’s Reappointment

    Biden is staying at his Rehoboth Beach home in Delaware while continuing to perform presidential duties.

    Vaccine Stocks To Watch: Novovax, Inc. (NASDAQ:NVAX), Moderna, Inc. (NASDAQ:MRNA) and Pfizer Inc. (NYSE:PFE) are all making new Covid vaccines that should be available before the end of September, the New York Times reported.

    The Novavax vaccine will target JN.1, the variant that was prominent in the winter and spring.

    Pfizer and Moderna are developing shots aimed at KP.2, which accounts for about one in four new cases. Two related variants, KP.3 and LB.1, are the culprint behind more than half of new cases, the Times said.

    All three variants are descendants of JN.1, so each of the vaccines is expected to be effective against them.

    NVAX, MRNA, PFE Price Action: Novovax shares were down 5.7% to $14.94 late in Thursday’s session. Moderna was down 2.16% to $121.37. Pfizer is down 1.07% at $29.70.

    Exchange-traded funds that hold shares of Pfizer, which has the largest market capitalization of the group of vaccine developers at $169 billion, declined in Thursday afternoon trading.

    • First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTHX) fell 0.35%.
    • First Trust Morningstar Dividend Leaders Index Fund (NYSE:FDL) slipped 0.69%.
    • Invesco Pharmceuticals ETF (NYSE:PJP) slid 0.55%.
    • Harbor Health Care ETF (NYSE:MEDI) lost 0.33%.
    • Invesco S&P Ultra dividend Revenue ETF (NYSE:RDIV) declined 0.66%.

    Read Now:

    • Moderna, Regeneron Pharmaceuticals And 2 Other Stocks Insiders Are Selling

    Photo via Shutterstock.

    Get the next $MRNA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MRNA
    $NVAX
    $PFE

    CompanyDatePrice TargetRatingAnalyst
    Pfizer Inc.
    $PFE
    3/2/2026$35.00Hold → Buy
    Argus
    Pfizer Inc.
    $PFE
    2/25/2026$25.00Underperform
    RBC Capital Mkts
    Pfizer Inc.
    $PFE
    2/20/2026$25.00Underweight
    Barclays
    Pfizer Inc.
    $PFE
    2/12/2026$27.00Outperform → Neutral
    Daiwa Securities
    Moderna Inc.
    $MRNA
    1/28/2026$25.00Equal Weight
    Barclays
    Pfizer Inc.
    $PFE
    1/7/2026$25.00Neutral
    UBS
    Moderna Inc.
    $MRNA
    1/7/2026$34.00Neutral
    UBS
    Moderna Inc.
    $MRNA
    12/12/2025$30.00Hold
    Jefferies
    More analyst ratings

    $MRNA
    $NVAX
    $PFE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Pfizer upgraded by Argus with a new price target

    Argus upgraded Pfizer from Hold to Buy and set a new price target of $35.00

    3/2/26 8:00:47 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on Pfizer with a new price target

    RBC Capital Mkts initiated coverage of Pfizer with a rating of Underperform and set a new price target of $25.00

    2/25/26 7:53:28 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Pfizer with a new price target

    Barclays initiated coverage of Pfizer with a rating of Underweight and set a new price target of $25.00

    2/20/26 8:25:15 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRNA
    $NVAX
    $PFE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Bancel Stephane bought $5,004,318 worth of shares (160,314 units at $31.22) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/4/25 4:27:16 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Sagan Paul bought $1,004,251 worth of shares (31,620 units at $31.76) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/4/25 4:24:36 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Blaylock Ronald E bought $499,072 worth of shares (19,457 units at $25.65), increasing direct ownership by 236% to 27,707 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    2/14/25 5:16:36 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRNA
    $NVAX
    $PFE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NYSE Content Update: Alysa Liu Rings NYSE Bell After Winning Two Gold Medals

    NYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK, March 4, 2026 /CNW/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.  Ashley Mastronardi delivers the pre-market update on March 4thEquities are volatile amid the ongoing conflict in the Middle East, with President Trump saying late Tuesday that the U.S. will provide risk insurance to all maritime trade in the Persian Gulf.Two-time Olympic gold-medalist figure skater Alysa Liu joined Kristen Scholer for an interview from the Rink at Rockefeller

    3/4/26 8:55:00 AM ET
    $ICE
    $PFE
    $SMWB
    Investment Bankers/Brokers/Service
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ParaZero Strengthens Global Sales Leadership with Appointment of Bat-Sheva Noy as VP

    Kfar Saba, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (NASDAQ:PRZO) (the "company" or "ParaZero"), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, recently announced the appointment of Bat-Sheva Noy as its new Vice President of Global Sales. Ms. Noy brings more than 20 years of extensive commercial and leadership experience, with particular expertise in strategic planning, market access, and leading cross-functional teams. Most recently, from 2020 to 2025, she served as the Business Unit Lead for Rare Diseases at Pfizer Israel ((a subsidiary of Pfizer Inc., NYSE:PFE). In that

    3/4/26 8:32:00 AM ET
    $PFE
    $PRZO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Military/Government/Technical
    Industrials

    Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight

    LAS VEGAS, March 2, 2026 /PRNewswire/ -- The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/OHARA Pharmaceutical), Tovecimig (CTX-009) (Compass Therapeutics), Lenvatinib mesylate (LENVIMA) (Merck/Eisai), and others will further boost the market growth. Recently published Biliary Tract Cancer Market Insights report includes a comprehensive understanding of current

    3/2/26 5:31:00 PM ET
    $BOLD
    $CMPX
    $INCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Commercial Physical & Biological Resarch

    $MRNA
    $NVAX
    $PFE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    10/25/24 2:48:21 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for HYMPAVZI issued to PFIZER INC

    Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

    10/15/24 2:57:27 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

    For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

    10/11/24 2:12:15 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRNA
    $NVAX
    $PFE
    SEC Filings

    View All

    SEC Form 10-K filed by Pfizer Inc.

    10-K - PFIZER INC (0000078003) (Filer)

    2/26/26 12:44:01 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novavax Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NOVAVAX INC (0001000694) (Filer)

    2/26/26 8:02:10 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Novavax Inc.

    10-K - NOVAVAX INC (0001000694) (Filer)

    2/26/26 7:33:51 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MRNA
    $NVAX
    $PFE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Jacobs John C converted options into 150,167 shares and covered exercise/tax liability with 69,288 shares, increasing direct ownership by 98% to 225,680 units (SEC Form 4)

    4 - NOVAVAX INC (0001000694) (Issuer)

    3/5/26 6:03:17 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    EVP, CFO and Treasurer Kelly James Patrick converted options into 43,167 shares and covered exercise/tax liability with 20,850 shares, increasing direct ownership by 22% to 124,280 units (SEC Form 4)

    4 - NOVAVAX INC (0001000694) (Issuer)

    3/5/26 6:04:04 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    EVP, Chief Strategy Officer O'Hara Elaine converted options into 56,334 shares and covered exercise/tax liability with 22,429 shares, increasing direct ownership by 34% to 134,642 units (SEC Form 4)

    4 - NOVAVAX INC (0001000694) (Issuer)

    3/5/26 6:02:23 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MRNA
    $NVAX
    $PFE
    Financials

    Live finance-specific insights

    View All

    Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

    Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areasMultiple Material Transfer Agreements signed in 2025 and Q1 2026 with pharmaceutical companies, including major global pharmaceutical companies exploring the utility of Matrix-M for their vaccine portfolios Successful execution of Sanofi partnership with $225 million in milestones earned in full year 2025Total revenue of $147 million in the fourth quarter of 2025 and $1.1 billion for the full year 2025Continued advancement of early-stage pipeline with the intention to enter the clinic as early as 2027Year end 2025 Cash of $751 million Novavax exceeded its full year 2025 R&

    2/26/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

    Pfizer Inc. (NYSE:PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 10:30 a.m. EST. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcript and webcast replay of the discussion will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussion and will be accessible for at least 90 days. About Pfizer: Breakthrough

    2/23/26 10:00:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    GAITHERSBURG, Md., Feb. 19, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced it will report its fourth quarter and full year 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, February 26, 2026. Details of the event and replay are as follows:Conference call details:Date:February 26, 2026Time:8:30 a.m. ETURL to register phone:Register HereDial-in number:(888) 880-3330 (U.S.) or(+1) (646) 357-8766 (International)Webcast:ir.novavax.com/eventsParticipants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.Participants can als

    2/19/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MRNA
    $NVAX
    $PFE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Novavax Inc.

    SC 13G/A - NOVAVAX INC (0001000694) (Subject)

    11/12/24 4:46:17 PM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Novavax Inc.

    SC 13G/A - NOVAVAX INC (0001000694) (Subject)

    11/4/24 1:19:04 PM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Novavax Inc.

    SC 13G/A - NOVAVAX INC (0001000694) (Subject)

    7/10/24 6:16:55 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MRNA
    $NVAX
    $PFE
    Leadership Updates

    Live Leadership Updates

    View All

    ParaZero Strengthens Global Sales Leadership with Appointment of Bat-Sheva Noy as VP

    Kfar Saba, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (NASDAQ:PRZO) (the "company" or "ParaZero"), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, recently announced the appointment of Bat-Sheva Noy as its new Vice President of Global Sales. Ms. Noy brings more than 20 years of extensive commercial and leadership experience, with particular expertise in strategic planning, market access, and leading cross-functional teams. Most recently, from 2020 to 2025, she served as the Business Unit Lead for Rare Diseases at Pfizer Israel ((a subsidiary of Pfizer Inc., NYSE:PFE). In that

    3/4/26 8:32:00 AM ET
    $PFE
    $PRZO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Military/Government/Technical
    Industrials

    Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

    WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. Dr. Nader brings more than 30 years of leadership experience across the biotechnology and pharmaceutical industry and currently serves as an Independent Director of Moderna, Inc. (NASDAQ:MRNA), a glo

    2/23/26 4:01:00 PM ET
    $MRNA
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments